Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease

一种艰难梭菌、艰难梭菌毒素的技术，应用在化学仪器和方法、药物组合、抗细菌药等方向，能够解决治疗失败、复发等问题

Inactive Publication Date: 2016-05-04
IMMURON LIMITED
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The history of treatment for CDAD has included the use of vancomycin, metronidazole, and combinations of vancomycin and metronidazole, but there have been significant treatment failures and relapses in many published studies of antibiotic efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
  • Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
  • Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0187] The preparation of pharmaceutical compositions is well known in the art and has been described in many articles and textbooks, see, for example, Remington's Pharmaceutical Sciences, Gennaro A.R. ed., Mack Publishing Co., Easton, PA, 1990, especially pp. 1521- 1712 pages, fully incorporated herein by reference.

[0188] The pharmaceutical compositions of the invention may be administered and administered according to good medical practice.

[0189] The compositions of the invention may contain the active substances in free form and be administered directly to the subject to be treated. Formulations generally comprise at least one active ingredient as defined above together with one or more acceptable carriers thereof. Each carrier should be pharmaceutically and physiologically acceptable in terms of compatibility with the other ingredients and be innocuous to the patient.

[0190] Formulations include those suitable for oral, nasal, or parenteral (including subcutaneou...

Embodiment 10

[0223] Example 10 and Figure 11 demonstrated that administration of antibodies that bind to C. difficile endospores before and during / after infection with C. difficile is effective in treating and preventing C. difficile-associated disease, C. difficile-associated mortality and reducing the shedding of C. difficile and C. difficile spread after bacterial infection.

Embodiment 13

[0224] Example 13 and Figure 15 It is shown that administration of antibodies that bind to C. difficile vegetative cells prior to and during infection with C. difficile is effective in treating and preventing C. difficile-associated disease and C. difficile-associated mortality.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods and compositions for the treatment and / or prophylaxis of Clostridium difficile associated disease (CD AD). In particular, the invention relates to antibodies that bind to C. difficile antigens and are capable of inhibiting C. difficile infection, at least one symptom of C. difficile associated disease, shedding of C. difficile, and C. difficile associated mortality. The compositions of the present application comprise: mammalian or avian antibodies which bind to a C. difficile Toxin B; and mammalian or avian antibodies that bind to a C. difficile vegetative cell antigen and / or a C. difficile endospore antigen.

Description

technical field [0001] The present invention relates to methods and compositions for the treatment and / or prevention of Clostridium difficile-associated disease (CDAD). In particular, the invention relates to antibodies that bind to a C. difficile antigen and are capable of inhibiting C. difficile infection, at least one symptom of C. difficile-associated disease, C. difficile shedding, and C. difficile-associated mortality. Background technique [0002] Clostridium difficile is a Gram-positive anaerobic bacterium that is one of the most important causes of antibiotic-associated diarrhea in developed countries, causing significant morbidity and mortality and a considerable economic burden on healthcare systems. The incidence of diarrhea in hospitalized patients receiving antibiotics ranges from 3% to 29%. Clostridium difficile acts as a pathogenic microorganism in 10-25% of patients with antibiotic-associated diarrhea, in 50-75% of patients with antibiotic-associated coliti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K39/40A61P1/12A61P31/04
CPCA61K2039/505C07K2317/12C07K2317/76A61K2039/522C07K16/1282A61P1/12A61P31/04Y02A50/30A61K9/0053A61K39/40C07K16/04
Inventor D·里拉斯M·赫顿B·坎宁安L·李G·卡特J·鲁德
Owner IMMURON LIMITED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap